- Home
- Publications
- Publication Search
- Publication Details
Title
Bile Acids and FXR: Novel Targets for Liver Diseases
Authors
Keywords
-
Journal
Frontiers in Medicine
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-11
DOI
10.3389/fmed.2020.00544
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
- (2020) Kris V. Kowdley et al. JOURNAL OF HEPATOLOGY
- Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis
- (2020) Adriana Carino et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Obeticholic acid in primary biliary cholangitis
- (2019) Vignan Manne et al. CURRENT OPINION IN GASTROENTEROLOGY
- Direct and Indirect Effects of FGF15 and FGF19 on Liver Fibrosis Development
- (2019) J D Schumacher et al. HEPATOLOGY
- A Human-like Bile Acid Pool Induced by Deletion of Cyp2c70 Modulates Effects of Farnesoid X Receptor Activation in Mice
- (2019) Jan Freark de Boer et al. JOURNAL OF LIPID RESEARCH
- Regulations of bile acid metabolism in mouse models with hydrophobic bile acid composition
- (2019) Akira Honda et al. JOURNAL OF LIPID RESEARCH
- Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
- (2018) B. Hameed et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Animal models to study bile acid metabolism
- (2018) Jianing Li et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer
- (2018) Ting Liu et al. GASTROENTEROLOGY
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
- (2018) Rowan F. van Golen et al. Scientific Reports
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review
- (2017) Duminda Suraweera et al. LIVER INTERNATIONAL
- Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice
- (2017) Bérengère Benoit et al. NATURE MEDICINE
- The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis
- (2017) J.D. Schumacher et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells
- (2017) Kazuo Imagawa et al. Scientific Reports
- Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
- (2016) JE Edwards et al. CTS-Clinical and Translational Science
- Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis
- (2016) V. Ratziu et al. JOURNAL OF HEPATOLOGY
- Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
- (2016) Shogo Takahashi et al. JOURNAL OF LIPID RESEARCH
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- A New Mdr2−/− Mouse Model of Sclerosing Cholangitis with Rapid Fibrosis Progression, Early-Onset Portal Hypertension, and Liver Cancer
- (2015) Naoki Ikenaga et al. AMERICAN JOURNAL OF PATHOLOGY
- Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
- (2015) Gideon M. Hirschfield et al. GASTROENTEROLOGY
- Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers
- (2015) Willscott E. Naugler et al. GASTROENTEROLOGY
- Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice
- (2015) Mei Zhou et al. HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21
- (2015) Bryn M. Owen et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Bile acid signaling and biliary functions
- (2015) Hannah Jones et al. Acta Pharmaceutica Sinica B
- Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis
- (2014) Yang Jiao et al. ACTA PHARMACOLOGICA SINICA
- Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2
- (2014) Runping Liu et al. HEPATOLOGY
- Genome-Wide Binding and Transcriptome Analysis of Human Farnesoid X Receptor in Primary Human Hepatocytes
- (2014) Le Zhan et al. PLoS One
- Repression of Farnesoid X Receptor Contributes to Biliary Injuries of Liver Grafts Through Disturbing Cholangiocyte Bile Acid Transport
- (2013) L. Cheng et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway
- (2013) Dongju Jung et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism
- (2013) Geneviève Marcelin et al. Molecular Metabolism
- Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
- (2012) M. J. Potthoff et al. GENES & DEVELOPMENT
- Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
- (2012) Bo Kong et al. HEPATOLOGY
- Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
- (2012) Chaofeng Yang et al. PLoS One
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
- (2011) Matthew J. Potthoff et al. Cell Metabolism
- SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts
- (2011) Barbara Renga et al. INFLAMMATION RESEARCH
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- The bile acid sensor FXR regulates insulin transcription and secretion
- (2010) Barbara Renga et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine
- (2009) Ann M. Thomas et al. HEPATOLOGY
- Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice
- (2009) Heping Yang et al. HEPATOLOGY
- Fibroblast Growth Factor-19, a Novel Factor That Inhibits Hepatic Fatty Acid Synthesis
- (2009) Sushant Bhatnagar et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis
- (2009) Songwen Zhang et al. JOURNAL OF HEPATOLOGY
- FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats
- (2009) Sabrina Cipriani et al. JOURNAL OF LIPID RESEARCH
- The FGF family: biology, pathophysiology and therapy
- (2009) Andrew Beenken et al. NATURE REVIEWS DRUG DISCOVERY
- Compensatory Induction of Liver Efflux Transporters in Response to ANIT-Induced Liver Injury Is Impaired in FXR-Null Mice
- (2009) Yue J. Cui et al. TOXICOLOGICAL SCIENCES
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started